Abstract
Patients undergoing this surgical procedure have been shown to have moderate to severe postoperative pain. Zynrelef (HTX-011) is an extended-release, dual-acting local anesthetic (DALA) formulation comprising bupivacaine and low-dose meloxicam in a controlled-diffusion polymer that allows for controlled delivery of active ingredients over 72 hours. HTX-011 has demonstrated superior postoperative pain management and limited opioid use compared with the standard-of-care local anesthetic bupivacaine hydrochloride (HCL) and saline placed in randomized, controlled registration studies of patients undergoing bunionectomy, herniorrhaphy, and TKA (total knee arthroplasty).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have